Xiaomei Zhang

Xiaomei Zhang

Auto-generated profile, based on publicly available information

Xiaomei Zhang

Sydney Infectious Diseases Institute (Sydney ID), Faculty of Medicine & Health, The University of Sydney, Sydney, New South Wales, Australia

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2015 in Cancer Science
Verified
Journal Article
Open access
PDF file
YFYingying Feng
Yingying Feng
LLLing Li
Ling Li
XZXiaomei Zhang
Xiaomei Zhang
YZYunjing Zhang
Yunjing Zhang
YLYingchun Liang
Yingchun Liang
QYQinong Ye
Qinong Ye
Hematopoietic pre‐B cell leukemia transcription factor interacting protein (HPIP) has been shown to play an important role in the development and progression of some cancers. However, the role of HPIP in gastric cancer (GC) is unclear. Here, we show that HPIP is upregulated in most GC patients and promotes GC cell proliferation, migration, and invasion. In GC patients, HPIP positively associates with tumor size and nodal metastasis, and negatively associates with tumor differentiation. Hematopoietic pre‐B cell leukemia transcription factor interacting protein increases GC cell proliferation through activation of G1/S and G2/M cell cycle transitions, accompanied by a marked increase of the positive cell cycle regulators, including cyclin D1, cyclin A, and cyclin B1. Hematopoietic pre‐B cell leukemia transcription factor interacting protein enhances GC cell migration and invasion, and modulates epithelial–mesenchymal transition, which plays a key role in cancer cell migration and invasion. These data underscore the critical role of HPIP in GC cell proliferation and progression and suggest that HPIP inhibition may be a useful therapeutic strategy for GC treatment.

24 October 2023 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
XZXiaomei Zhang
Xiaomei Zhang
CLConnie Lam
Connie Lam
EMElena Martinez
Elena Martinez
ESEby Sim
Eby Sim
TCTaryn Crighton
Taryn Crighton
VSVitali Sintchenko
Vitali Sintchenko
Minority variants of Mycobacterium tuberculosis harboring mutations conferring resistance can become dominant populations during tuberculosis (TB) treatment, leading to treatment failure. Our understanding of drug-resistant within-host subpopulations and the frequency of resistance-conferring mutations in minority variants remains limited. M. tuberculosis sequences recovered from liquid cultures of culture-confirmed TB cases notified between January 2017 and December 2021 in New South Wales, Australia were examined. Potential drug resistance-conferring minority variants were identified using LoFreq, and mixed populations of different M. tuberculosis strains (≥100 SNPs apart) were examined using QuantTB. A total of 1831 routinely sequenced M. tuberculosis strains were included in the analysis. Drug resistance-conferring minority variants were detected in 3.5% (65/1831) of sequenced cultures; 84.6% (55/65) had majority strains that were drug susceptible and 15.4% (10/65) had majority strains that were drug resistant. Minority variants with high-confidence drug resistance-conferring mutations were 1.5 times more common when the majority strains were drug resistant. Mixed M. tuberculosis strain populations were documented in 10.0% (183/1831) of specimens. Minority variants with high-confidence drug resistance-conferring mutations were more frequently detected in mixed M. tuberculosis strain populations (2.7%, 5/183) than in single strain populations (0.6%, 10/1648; P = 0.01). Drug-resistant minority variants require monitoring in settings that implement routine M. tuberculosis sequencing. The frequency with which drug-resistant minority variants are detected is likely influenced by pre-culture requirement. Culture-independent sequencing methods should provide a more accurate reflection of drug-resistant subpopulations.

1 September 2016 in Tetrahedron Letters
Verified
Journal Article
Closed access
ZLZaigang Luo
Zaigang Luo
YFYuyu Fang
Yuyu Fang
YZYu Zhao
Yu Zhao
XXXuemei Xu
Xuemei Xu
CFCheng-Tao Feng
Cheng-Tao Feng
JHJie He
Jie He

20 March 2026 in The Lancet Microbe
Verified
Journal Article
Open access
MNMai Nguyen
Mai Nguyen
EMEmily Lai-Ho MacLean
Emily Lai-Ho MacLean
XZXiaomei Zhang
Xiaomei Zhang
SGSophia B Georghiou
Sophia B Georghiou
HXHui Xia
Hui Xia
GFGreg Fox
Greg Fox
The paucity of diagnostic tests for isoniazid-resistant tuberculosis is concerning, given its status as the most common form of drug-resistant tuberculosis and a gateway to multidrug-resistant diseases. Molecular drug-susceptibility testing has improved access to timely diagnosis of rifampicin-resistant tuberculosis, but testing for isoniazid-resistant tuberculosis still remains rare. In this Review, we assessed the characteristics of molecular drug-susceptibility testing for detection of isoniazid-resistant tuberculosis, referencing the WHO target product profiles. 9243 citations were screened to select 238 studies published between 2000 and 2024. The diagnostics options have expanded rapidly since 2020, with 27 nucleic acid amplification tests, eight line probe assays, five DNA microarrays, two targeted next-generation sequencing platforms, and two whole-genome sequencing platforms. Most of the evaluated molecular drug-susceptibility tests met diagnostic performance targets but were often complex and costly. Although a few low-complexity nucleic acid amplification tests met key target product profile criteria, additional field validation and greater efforts are needed to ensure optimal feasibility and affordability for low-resource settings.

20 June 2024 in iScience
Verified
Journal Article
Open access
XZXiaomei Zhang
Xiaomei Zhang
CLConnie Lam
Connie Lam
ESEby Sim
Eby Sim
EMElena Martinez
Elena Martinez
TCTaryn Crighton
Taryn Crighton
VSVitali Sintchenko
Vitali Sintchenko
Understanding the differences between Mycobacterium tuberculosis strains isolated from respiratory and non-respiratory sources may inform clinical care and control strategies. We examined demographic and genomic characteristics of all culture-confirmed M. tuberculosis cultures isolated from respiratory and non-respiratory sources in New South Wales, Australia, from January 2017 to December 2021, using logistic regression models. M. tuberculosis strains from 1,831 patients were sequenced; 64.7% were from respiratory, 32.1% from non-respiratory, and 2.2% from both sources. Female patients had more frequent isolation from a non-respiratory source (p = 0.03), and older adults (≧65 years) from a respiratory source (p < 0.0001). Lineage 2 strains were relatively over-represented among respiratory isolates (p = 0.01). Among 39 cases with sequenced isolates from both sources, 43.6% had 1–10 single nucleotide polymorphism differences. The finding that older adults were more likely to have M. tuberculosis isolated from respiratory sources has relevance for TB control given the expected rise of TB among older adults.

1 January 2021 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
RDRongrong Deng
Rongrong Deng
CWChangzheng Wang
Changzheng Wang
YYYi Ye
Yi Ye
LGLiyao Gou
Liyao Gou
ZFZhongxiao Fu
Zhongxiao Fu
CLChengbin Li
Chengbin Li
Background: Although there are many COVID-19 case series studies, few studies report the relationship between variations in blood cell parameters and inflammatory factors and disease severity. This study aims to describe the dynamic trends in COVID-19 blood cell parameters and inflammatory factors. Methods: Ninety-two patients with confirmed COVID-19 at Jingzhou Central Hospital, Hubei Province, China, between January 23, 2020, and April 10, 2020, were enrolled. Epidemiological data, clinical information, and laboratory test results were collected and analyzed. Results: As patient age increased, disease severity increased (P<0.0001). The inflammatory factor C-reactive protein (CRP) showed a gradual increasing trend with disease aggravation. Based on dynamic change graphs, CRP in all patients with severe and critical COVID-19 initially increased and then decreased; however, CRP in patients with a good prognosis did not increase again after the initial decline (50 mg/L) 1 week after the initial decrease and continued to fluctuate at a high level. Lymphocyte count (LYM#) in patients with severe and critical disease was significantly lower (1×109/L), but patients with a poor prognosis continued to have a low LYM#. Conclusions: CRP and LYM# showed strong correlation with disease progression, suggesting that these parameters could be used to monitor changes in patient condition.